Pluristyx Revenue
Biotechnology Research • 
201 Elliott Ave W, Seattle, United States • 11-20 Employees
Pluristyx revenue & valuation
| Annual revenue | $4,100,000 |
| Revenue per employee | $274,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $13,200,000 |
| Total funding | No funding |
Key Contacts at Pluristyx
Benjamin Fryer
Co-Founder And Ceo
Steve Geelhood
Senior Director Commercial Operations
Company overview
| Headquarters | 201 Elliott Ave W, Seattle, Washington 98119, US |
| Phone number | +18885889935 |
| Website | |
| Keywords | Gene Therapy, Consulting, Manufacturing, Cryopreservation, Drug Development, Regenerative Medicine, Stem Cells, Cell Therapy, Process Development, Scale-Up, Gmp Banking, Gene Editing, Ipsc, Cmc Project Management, Car T-Cells, Pluripotent Stem Cells, Reprogramming |
| Founded | 2018 |
| Employees | 11-20 |
| Socials |
Pluristyx Email Formats
Pluristyx uses 2 email formats. The most common is {first initial}.{last name} (e.g., j.doe@pluristyx.com), used 75% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}.{last name} | j.doe@pluristyx.com | 75% |
{first name}.{last name} | john.doe@pluristyx.com | 25% |
About Pluristyx
Pluristyx is a pioneering company at the forefront of stem cell technologies. With a mission to revolutionize the field of regenerative medicine, Pluristyx develops innovative solutions that empower breakthroughs in stem cell therapies. The company's proprietary platform, panCELLa, represents a transformative leap in stem cell research, offering enhanced freedom to operate and unparalleled potential for medical advancements at a significantly accelerated timeline. Operating from two cutting-edge North American sites, Pluristyx is dedicated to driving progress and innovation in the realm of stem cell therapies. In July of 2023 Pluristyx and panCELLa merged. Pluristyx offers a portfolio of iPSC-based products and services to provide end-to-end client support in early product development, while panCELLa offers an array of unique and effective technologies with particular strength in gene editing. As one company, Pluristyx and panCELLa offer an enlarged portfolio whose long-term focus is to become the global leader in clinical-grade, genetically modified, “off-the-shelf” iPSCs with the lowest barrier to entry for cell therapy development, providing clients with the fastest speed to clinic and the best route to commercialization.
Employees by Management Level
Total employees: 11-20
Seniority
Employees
Employees by Department
Pluristyx has 6 employees across 4 departments.
Departments
Number of employees
Pluristyx Tech Stack
Discover the technologies and tools that power Pluristyx's digital infrastructure, from frameworks to analytics platforms.
Security
WordPress themes
Analytics
JavaScript libraries
Page builders
CDN
JavaScript libraries
Analytics
Webmail
Miscellaneous
Programming languages
United Kingdom
Hong Kong
Frequently asked questions
4.8
40,000 users
